OBJECTIVE: Calcium channel blocker (CCB) toxicity, in particular that induced by verapamil and diltiazem, presents clinical challenges with no true antidote. Levosimendan, a calcium sensitizer, improves cardiac contractility in patients with heart failure. We tested the hypothesis that calcium channel sensitization will prolong survival in a rat model of severe verapamil poisoning. METHODS: This was a blinded, randomized, controlled animal study. Wistar rats (mean weight, 371 +/- 50 g) were used. Verapamil (2.5 mg/ml) was infused at a rate of 37.5 mg/kg per hour. Bolus doses of levosimendan (5 microg/mL) were given at 0 min (12 microg/kg) and 5 min (18 microg/kg); saline control was of equal volume. The rats were intubated and maintained under general anesthesia with isoflurane. Electrocardiographic activity and core temperature were monitored during the poisoning and treatment phases. Each rat underwent femoral vein cannulation and was then randomized, in blinded fashion, to receive either levosimendan or an equal volume of saline at 0 and 5 minutes. Death, defined as 1 minute of asystole, was used as the primary endpoint. RESULTS: Rats treated with levosimendan died before the control group (7.37 +/- 0.7 min [n=7] vs. 16.4 +/- 4.2 [n=7] [ p=.053]). All animals experienced bradycardia prior to asystole. DISCUSSION: Although levosimendan has the ability to sensitize and enhance binding of troponin C to Ca2+, this study did not show an improvement in survival time in the setting of verapamil toxicity. This may be attributed to levosimendan's inhibition of phosphodiesterase, which possibly exacerbated the CCB-induced hypotension. CONCLUSION: In this rat model, levosimendan as a solitary antidotal treatment for verapamil toxicity was not beneficial.
OBJECTIVE:Calcium channel blocker (CCB) toxicity, in particular that induced by verapamil and diltiazem, presents clinical challenges with no true antidote. Levosimendan, a calcium sensitizer, improves cardiac contractility in patients with heart failure. We tested the hypothesis that calcium channel sensitization will prolong survival in a rat model of severe verapamilpoisoning. METHODS: This was a blinded, randomized, controlled animal study. Wistar rats (mean weight, 371 +/- 50 g) were used. Verapamil (2.5 mg/ml) was infused at a rate of 37.5 mg/kg per hour. Bolus doses of levosimendan (5 microg/mL) were given at 0 min (12 microg/kg) and 5 min (18 microg/kg); saline control was of equal volume. The rats were intubated and maintained under general anesthesia with isoflurane. Electrocardiographic activity and core temperature were monitored during the poisoning and treatment phases. Each rat underwent femoral vein cannulation and was then randomized, in blinded fashion, to receive either levosimendan or an equal volume of saline at 0 and 5 minutes. Death, defined as 1 minute of asystole, was used as the primary endpoint. RESULTS:Rats treated with levosimendan died before the control group (7.37 +/- 0.7 min [n=7] vs. 16.4 +/- 4.2 [n=7] [ p=.053]). All animals experienced bradycardia prior to asystole. DISCUSSION: Although levosimendan has the ability to sensitize and enhance binding of troponin C to Ca2+, this study did not show an improvement in survival time in the setting of verapamiltoxicity. This may be attributed to levosimendan's inhibition of phosphodiesterase, which possibly exacerbated the CCB-induced hypotension. CONCLUSION: In this rat model, levosimendan as a solitary antidotal treatment for verapamiltoxicity was not beneficial.
Authors: Leonardo De Luca; Wilson S Colucci; Markku S Nieminen; Barry M Massie; Mihai Gheorghiade Journal: Eur Heart J Date: 2006-04-27 Impact factor: 29.983
Authors: Melisa W Lai; Wendy Klein-Schwartz; George C Rodgers; Joseph Y Abrams; Deborah A Haber; Alvin C Bronstein; Kathleen M Wruk Journal: Clin Toxicol (Phila) Date: 2006 Impact factor: 4.467
Authors: M T Slawsky; W S Colucci; S S Gottlieb; B H Greenberg; E Haeusslein; J Hare; S Hutchins; C V Leier; T H LeJemtel; E Loh; J Nicklas; D Ogilby; B N Singh; W Smith Journal: Circulation Date: 2000-10-31 Impact factor: 29.690
Authors: P Pollesello; M Ovaska; J Kaivola; C Tilgmann; K Lundström; N Kalkkinen; I Ulmanen; E Nissinen; J Taskinen Journal: J Biol Chem Date: 1994-11-18 Impact factor: 5.157
Authors: Alexandre Mebazaa; Markku S Nieminen; Milton Packer; Alain Cohen-Solal; Franz X Kleber; Stuart J Pocock; Roopal Thakkar; Robert J Padley; Pentti Põder; Matti Kivikko Journal: JAMA Date: 2007-05-02 Impact factor: 56.272
Authors: David H Jang; Sean Donovan; Lewis S Nelson; Theodore C Bania; Robert S Hoffman; Jason Chu Journal: Ann Emerg Med Date: 2014-10-23 Impact factor: 5.721
Authors: Maude St-Onge; Kurt Anseeuw; Frank Lee Cantrell; Ian C Gilchrist; Philippe Hantson; Benoit Bailey; Valéry Lavergne; Sophie Gosselin; William Kerns; Martin Laliberté; Eric J Lavonas; David N Juurlink; John Muscedere; Chen-Chang Yang; Tasnim Sinuff; Michael Rieder; Bruno Mégarbane Journal: Crit Care Med Date: 2017-03 Impact factor: 7.598
Authors: M St-Onge; P-A Dubé; S Gosselin; C Guimont; J Godwin; P M Archambault; J-M Chauny; A J Frenette; M Darveau; N Le Sage; J Poitras; J Provencher; D N Juurlink; R Blais Journal: Clin Toxicol (Phila) Date: 2014-10-06 Impact factor: 4.467